Search results
Added:
1 year ago
Source:
ACC 2025
Watch our comprehensive coverage of ACC 2025's top trials here.The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago.View the full programme here.Late-Breaking Clinical Trials I (Session 102)Saturday 29th March, 09…
View more
Added:
10 months ago
Source:
Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide…
View more
Added:
2 years ago
Source:
ESC Congress
The European Society of Cardiology has revealed the late-breaking science sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30th August to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View…
View more
Added:
8 months ago
Source:
Radcliffe Cardiology
A large-scale meta-analysis of individual patient data has found that beta-blocker therapy does not reduce the risk of major adverse cardiovascular events in patients with a preserved left ventricular ejection fraction (LVEF) following a myocardial infarction (MI).¹ The findings, from the Beta-Blocker Trialists’ Collaboration Study Group, question the routine use of this drug class in this…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis…
View more
Added:
10 months ago
Source:
Radcliffe Cardiology
A prespecified secondary analysis of the DANFLU-2 trial suggests that a high-dose inactivated influenza vaccine (HD-IIV) may offer greater protection against cardiovascular-related hospitalisations in older adults compared to a standard-dose vaccine (SD-IIV).¹˒² While the trial’s primary endpoint was not met, these exploratory findings point to a potential benefit in reducing the burden of…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
The role of long-term beta-blocker therapy following a myocardial infarction (MI) in patients without heart failure remains a subject of clinical debate, particularly in the modern era of reperfusion and secondary prevention. The BETAMI–DANBLOCK trial sought to address this evidence gap by evaluating the efficacy of beta-blockers in this specific patient population.¹BETAMI–DANBLOCK was an open…
View more
REBOOT-CNIC: Beta-Blockers Show No Benefit Post-MI in Patients with Preserved Ejection Fraction
Added:
10 months ago
Source:
Radcliffe Cardiology
News
Added:
8 months ago
Source:
Radcliffe Cardiology
Differentiating cardiac amyloidosis (CA) from its phenotypic mimics remains a clinical challenge. A new study published in the European Heart Journal details the development and validation of a novel artificial intelligence (AI) model that can accurately screen for CA using only a single apical four-chamber echocardiogram video clip.¹This retrospective, multisite, multiethnic study first trained…
View more
Added:
10 months ago
Source:
Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time…
View more